See more : Chip Eng Seng Corporation Ltd (C29.SI) Income Statement Analysis – Financial Results
Complete financial analysis of ProMIS Neurosciences, Inc. (PMN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ProMIS Neurosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Oatly Group AB (OTLY) Income Statement Analysis – Financial Results
- MicroAlgo Inc. (VENA) Income Statement Analysis – Financial Results
- Plant Veda Foods Ltd. (PLVFF) Income Statement Analysis – Financial Results
- IRRAS AB (publ) (IRRAS.ST) Income Statement Analysis – Financial Results
- Delphax Technologies Inc. (DLPX) Income Statement Analysis – Financial Results
ProMIS Neurosciences, Inc. (PMN)
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 8.14K | 1.40K | 920.18 | 348.74 | 7.87K | 2.00K | 14.37K | 134.18K | 48.67K | 91.09K | 1.23M | 176.16K | 193.63K | 464.02K | 219.92K | 31.31K |
| Cost of Revenue | 10.44M | 21.78M | 5.85M | 3.18M | 4.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -10.44M | -21.78M | -5.84M | -3.18M | -4.73M | 348.74 | 7.87K | 2.00K | 14.37K | 134.18K | 48.67K | 91.09K | 1.23M | 176.16K | 193.63K | 464.02K | 219.92K | 31.31K |
| Gross Profit Ratio | 0.00% | 0.00% | -71,796.88% | -227,041.82% | -514,509.20% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 7.88M | 16.09M | 4.95M | 2.50M | 3.63M | 5.44M | 3.15M | 1.39M | 763.96K | 1.27M | 1.77M | 2.04M | 3.25M | 3.62M | 3.27M | 6.06M | 2.95M | 944.20K |
| General & Administrative | 7.39M | 7.29M | 3.31M | 1.95M | 2.04M | 2.02M | 1.64M | 1.17M | 682.26K | 898.06K | 476.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -1.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.38M | 7.29M | 3.31M | 1.95M | 2.04M | 2.02M | 1.64M | 1.17M | 682.26K | 898.06K | 476.13K | 536.21K | 1.20M | 1.17M | 824.00K | 1.22M | 885.47K | 351.62K |
| Other Expenses | -5.81M | 115.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.96K | 212.41K | 154.43K | 178.36K | 163.50K | 51.04K | 9.64K |
| Operating Expenses | 8.45M | 23.38M | 8.26M | 4.44M | 5.66M | 7.46M | 4.79M | 2.56M | 1.45M | 2.17M | 2.24M | 2.65M | 4.66M | 4.94M | 4.27M | 7.45M | 3.89M | 1.31M |
| Cost & Expenses | 18.90M | 23.38M | 8.26M | 4.44M | 5.66M | 7.46M | 4.79M | 2.56M | 1.45M | 2.17M | 2.24M | 2.65M | 4.66M | 4.94M | 4.27M | 7.45M | 3.89M | 1.31M |
| Interest Income | 0.00 | 0.00 | 4.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.29K | 13.53K | 46.99K | 131.51K | 193.63K | 193.63K | 0.00 | 0.00 |
| Interest Expense | -201.39K | 282.06K | 415.03K | 0.00 | 0.00 | 0.00 | 5.65K | 15.89K | 23.98K | 0.00 | 2.29K | 13.53K | 46.99K | 131.51K | 193.63K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 28.04K | 15.19K | 45.83K | 12.33K | 6.55K | 4.90K | 5.31K | 4.96K | 5.50K | 14.78K | 49.45K | 75.96K | 212.41K | 154.43K | 178.36K | 163.50K | 51.04K | 9.64K |
| EBITDA | -17.81M | -29.88M | -9.33M | -4.43M | -5.66M | -7.46M | -4.78M | -2.55M | -1.51M | -2.88M | -2.02M | -2.15M | -2.49M | -3.13M | -4.61M | -3.90M | -6.82M | -3.62M |
| EBITDA Ratio | 0.00% | 0.00% | -100,802.23% | -315,985.67% | -614,617.22% | -2,139,026.95% | -60,699.29% | -127,551.65% | -9,929.36% | -1,508.22% | -4,408.57% | -2,730.51% | -261.17% | -2,617.02% | -2,013.48% | -1,470.16% | -1,645.59% | -2,724.12% |
| Operating Income | -18.90M | -23.38M | -8.25M | -4.44M | -5.66M | -7.46M | -4.78M | -2.56M | -1.51M | -2.04M | -2.19M | -2.56M | -3.43M | -4.76M | -4.08M | -6.99M | -3.67M | -1.69M |
| Operating Income Ratio | 0.00% | 0.00% | -101,363.57% | -316,865.81% | -615,329.37% | -2,140,431.58% | -60,766.72% | -127,799.59% | -10,519.49% | -1,519.23% | -4,510.18% | -2,813.90% | -278.43% | -2,704.69% | -2,105.59% | -1,505.39% | -1,668.80% | -5,382.95% |
| Total Other Income/Expenses | 1.39M | 7.20M | -1.50M | 1.22M | 0.00 | 0.00 | -5.65K | -11.82K | -17.28K | -853.75K | 0.00 | 40.59K | 13.50 | 3.34M | 0.00 | 4.08M | 3.32M | 1.98M |
| Income Before Tax | -17.51M | -18.06M | -9.24M | -4.44M | -5.66M | -7.46M | -4.79M | -2.57M | -1.53M | -2.04M | -2.19M | -2.55M | -3.43M | -4.76M | -4.08M | -6.99M | -3.67M | -1.69M |
| Income Before Tax Ratio | 0.00% | 0.00% | -113,562.83% | -316,865.81% | -615,329.37% | -2,140,431.58% | -60,838.50% | -128,390.00% | -10,639.79% | -1,519.23% | -4,505.49% | -2,799.05% | -278.43% | -2,704.69% | -2,105.59% | -1,505.39% | -1,668.80% | -5,388.21% |
| Income Tax Expense | -167.90K | -5.32M | 415.03K | 0.14 | 0.00 | -156.24K | 5.65K | 11.82K | 17.28K | 0.91 | -2.29K | 2.55M | 3.43M | 4.76M | 4.08M | 6.99M | 3.67M | 1.69M |
| Net Income | -17.51M | -12.74M | -9.66M | -4.44M | -5.66M | -7.46M | -4.79M | -2.57M | -1.53M | -2.04M | -2.19M | -2.55M | -3.43M | -4.76M | -4.08M | -6.99M | -3.67M | -1.69M |
| Net Income Ratio | 0.00% | 0.00% | -118,662.24% | -316,865.81% | -615,329.37% | -2,140,431.58% | -60,838.50% | -128,390.00% | -10,639.79% | -1,519.23% | -4,505.49% | -2,799.05% | -278.43% | -2,704.69% | -2,105.59% | -1,505.39% | -1,668.80% | -5,388.21% |
| EPS | -1.42 | -1.70 | -1.67 | -0.93 | -1.31 | -1.87 | -1.40 | -0.91 | -0.85 | -2.02 | -2.32 | -2.99 | -4.21 | -5.99 | -5.83 | -10.15 | -6.93 | -5.24 |
| EPS Diluted | -1.42 | -1.70 | -1.67 | -0.93 | -1.31 | -1.87 | -1.40 | -0.91 | -0.85 | -2.02 | -2.32 | -2.99 | -4.21 | -5.99 | -5.83 | -10.15 | -6.93 | -5.24 |
| Weighted Avg Shares Out | 12.29M | 7.50M | 5.79M | 4.76M | 4.33M | 3.99M | 3.43M | 2.83M | 1.80M | 1.01M | 945.75K | 854.13K | 813.26K | 795.18K | 699.76K | 688.30K | 529.29K | 321.77K |
| Weighted Avg Shares Out (Dil) | 12.29M | 7.50M | 5.79M | 4.76M | 4.33M | 3.99M | 3.43M | 2.83M | 1.80M | 1.01M | 945.75K | 854.13K | 813.26K | 795.18K | 699.76K | 688.30K | 529.29K | 321.77K |
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential target engagement in patients with Alzheimer's disease
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference
Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement Initiation of Phase 1b clinical trial in Alzheimer's disease patients planned for year-end 2024 CAMBRIDGE, Massachusetts and TORONTO, Ontario, Oct. 30, 2024 (GLOBE...
ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD),...
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 05, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, Chief...
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that Neil Warma, interim...
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference
Preclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for potential Alzheimer's disease vaccine
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fluid (CSF) suggestive of its potential for target engagement in Alzheimer's disease patients
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the warrants subject to shareholder approval
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease on track for mid-2024 Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease on track for mid-2024
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies
Source: https://incomestatements.info
Category: Stock Reports